EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Vasopressin Receptor Antagonist Tolvaptan Counteracts Tumor Growth in a Murine Xenograft Model of Small Cell Lung Cancer

Laura Naldi, Benedetta Fibbi, Simone Polvani, Chiara Cirillo, Francesca Pasella, Francesca Bartolini, Francesca Romano, Alessandra Fanelli, Alessandro Peri iD, Giada Marroncini iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25158402 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Laura Naldi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pituitary Diseases and Sodium Alterations Unit, AOU Careggi, 50139 Florence, Italy. Hauptthemen laut MEDLINE: Tolvaptan, Antidiuretic Hormone Receptor Antagonists, Lung Neoplasms, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PRIN, Italian University and Research Ministry.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We have previously demonstrated that the vasopressin type 2 receptor (AVPR2) antagonist tolvaptan reduces cell proliferation and invasion and triggers apoptosis in different human cancer cell lines. To study this effect in vivo, a xenograft model of small cell lung cancer was developed in Fox1nu/nu nude mice through the subcutaneous inoculation of H69 cells, which express AVPR2. One group of mice (n = 5) was treated with tolvaptan for 60 days, whereas one group (n = 5) served as the control. A reduced growth was observed in the tolvaptan group in which the mean tumor volume was significantly smaller on day 60 compared to the control group. In the latter group, a significantly lower survival was observed. The analysis of excised tumors revealed that tolvaptan effectively inhibited the cAMP/PKA and PI3K/AKT signaling pathways. The expression of the proliferative marker proliferating cell nuclear antigen (PCNA) was significantly lower in tumors excised from tolvaptan-treated mice, whereas the expression levels of the apoptotic marker caspase-3 were higher than those in control animals. Furthermore, tumor vascularization was significantly lower in the tolvaptan group. Overall, these findings suggest that tolvaptan counteracts tumor progression in vivo and, if confirmed, might indicate a possible role of this molecule as an adjuvant in anticancer strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TolvaptanAntidiuretic Hormone Receptor AntagonistsLung NeoplasmsXenograft Model Antitumor AssaysCell ProliferationSmall Cell Lung CarcinomaReceptors, VasopressinMice, NudeAnimalsMiceHumansCell Line, TumorApoptosisSignal Transduction

Stichwörter der Autor:innen

hyponatremiasmall cell lung cancertolvaptanvasopressin receptor

Substanzen

TolvaptanAntidiuretic Hormone Receptor AntagonistsReceptors, Vasopressin

Autor:innen und Institutionen

  • Pituitary Diseases and Sodium Alterations Unit, AOU Careggi, 50139 Florence, Italy.
  • Endocrinology, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, AOU Careggi, 50139 Florence, Italy.
  • Gastroenterology Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50139 Florence, Italy.
  • Central Laboratory, Careggi University Hospital, 50139 Florence, Italy.

ORCID-Profile: Alessandro Peri, Giada Marroncini

Förderung

  • PRIN
  • Italian University and Research Ministry

Zitieren

APA

Naldi, L., Fibbi, B., Polvani, S., Cirillo, C., Pasella, F., Bartolini, F., Romano, F., Fanelli, A., Peri, A., & Marroncini, G. (2024). The Vasopressin Receptor Antagonist Tolvaptan Counteracts Tumor Growth in a Murine Xenograft Model of Small Cell Lung Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25158402

Vancouver

Naldi L, Fibbi B, Polvani S, Cirillo C, Pasella F, Bartolini F, et al. The Vasopressin Receptor Antagonist Tolvaptan Counteracts Tumor Growth in a Murine Xenograft Model of Small Cell Lung Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25158402

BibTeX
@article{Naldi2024,
  author = {Naldi, Laura and Fibbi, Benedetta and Polvani, Simone and Cirillo, Chiara and Pasella, Francesca and Bartolini, Francesca and Romano, Francesca and Fanelli, Alessandra and Peri, Alessandro and Marroncini, Giada},
  title = {The Vasopressin Receptor Antagonist Tolvaptan Counteracts Tumor Growth in a Murine Xenograft Model of Small Cell Lung Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25158402}
}
Kostenlos starten →